Financhill
Buy
56

BMY Quote, Financials, Valuation and Earnings

Last price:
$63.15
Seasonality move :
1.48%
Day range:
$60.27 - $63.11
52-week range:
$39.35 - $63.11
Dividend yield:
3.96%
P/E ratio:
--
P/S ratio:
2.57x
P/B ratio:
7.59x
Volume:
18.5M
Avg. volume:
12.2M
1-year change:
14.66%
Market cap:
$124B
Revenue:
$48.3B
EPS (TTM):
-$4.42

Analysts' Opinion

  • Consensus Rating
    Bristol-Myers Squibb has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 17 Hold ratings, and 1 Sell rating.
  • Price Target Upside
    According to analysts' consensus price target of $61.24, Bristol-Myers Squibb has an estimated upside of 0.25% from its current price of $61.09.
  • Price Target Downside
    According to analysts, the lowest downside price target is $37.00 representing 39.43% downside risk from its current price of $61.09.

Fair Value

  • According to the consensus of 22 analysts, Bristol-Myers Squibb has 0.25% upside to fair value with a price target of $61.24 per share.

BMY vs. S&P 500

  • Over the past 5 trading days, Bristol-Myers Squibb has overperformed the S&P 500 by 5.74% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Bristol-Myers Squibb does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Bristol-Myers Squibb has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Bristol-Myers Squibb reported revenues of $12.3B.

Earnings Growth

  • Bristol-Myers Squibb earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Bristol-Myers Squibb reported earnings per share of $0.04.
Enterprise value:
162.8B
EV / Invested capital:
2.47x
Price / LTM sales:
2.57x
EV / EBIT:
--
EV / Revenue:
3.37x
PEG ratio (5yr expected):
--
EV / Free cash flow:
11.68x
Price / Operating cash flow:
8.89x
Enterprise value / EBITDA:
51.39x
Gross Profit (TTM):
$34.3B
Return On Assets:
-9.42%
Net Income Margin (TTM):
-18.53%
Return On Equity:
-46.27%
Return On Invested Capital:
-13.01%
Operating Margin:
4.13%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $46.2B $45B $48.3B $11.5B $12.3B
Gross Profit $36B $34.3B $34.3B $8.7B $7.5B
Operating Income $9.1B $8.2B $5.9B $1.9B $510M
EBITDA $19.2B $19.4B $3.2B $4.5B $2.6B
Diluted EPS $2.95 $3.86 -$4.42 $0.87 $0.04
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $30.2B $33.3B $27.3B $31.8B $29.8B
Total Assets $118.5B $109.3B $96.8B $95.2B $92.6B
Current Liabilities $19.1B $21.9B $21.9B $22.3B $23.8B
Total Liabilities $80.6B $73.3B $65.7B $65.7B $76.2B
Total Equity $37.9B $36B $31.1B $29.5B $16.4B
Total Debt $50.7B $44.6B $39.3B $39.8B $49.6B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations $13.1B $13.9B $15.2B $4.3B $4.4B
Cash From Investing -$1.1B -$2.3B -$21.4B -$1.3B -$196M
Cash From Financing -$17B -$9.4B $5.1B $967M -$1.6B
Free Cash Flow $11.9B $12.7B $13.9B $3.9B $4.1B
BMY
Sector
Market Cap
$124B
$38.8M
Price % of 52-Week High
96.8%
46.15%
Dividend Yield
3.96%
0%
Shareholder Yield
2.14%
-0.74%
1-Year Price Total Return
14.66%
-38.9%
Beta (5-Year)
0.435
0.773
Dividend yield:
3.96%
Annualized payout:
$2.40
Payout ratio:
-54.35%
Growth streak:
3 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $59.53
200-day SMA
Buy
Level $51.27
Bollinger Bands (100)
Buy
Level 54.45 - 59.09
Chaikin Money Flow
Buy
Level 711.4M
20-day SMA
Buy
Level $57.36
Relative Strength Index (RSI14)
Buy
Level 65.92
ADX Line
Buy
Level 23.27
Williams %R
Neutral
Level -21.1076
50-day SMA
Buy
Level $57.52
MACD (12, 26)
Buy
Level 0.81
25-day Aroon Oscillator
Buy
Level 52
On Balance Volume
Neutral
Level 558.7M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (1.4991)
Sell
CA Score (Annual)
Level (-1.7489)
Buy
Beneish M-Score (Annual)
Level (-3.72)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-0.0536)
Buy
Piotroski F Score (Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Stock Forecast FAQ

In the current month, BMY has received 4 Buy ratings 17 Hold ratings, and 1 Sell ratings. The BMY average analyst price target in the past 3 months is $61.24.

  • Where Will Bristol-Myers Squibb Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Bristol-Myers Squibb share price will rise to $61.24 per share over the next 12 months.

  • What Do Analysts Say About Bristol-Myers Squibb?

    Analysts are divided on their view about Bristol-Myers Squibb share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bristol-Myers Squibb is a Sell and believe this share price will drop from its current level to $37.00.

  • What Is Bristol-Myers Squibb's Price Target?

    The price target for Bristol-Myers Squibb over the next 1-year time period is forecast to be $61.24 according to 22 Wall Street analysts, 4 of them rate the stock a Buy, 1 rates the stock a Sell, and 17 analysts rate the stock a Hold.

  • Is BMY A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Bristol-Myers Squibb is a Hold. 17 of 22 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of BMY?

    You can purchase shares of Bristol-Myers Squibb via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bristol-Myers Squibb shares.

  • What Is The Bristol-Myers Squibb Share Price Today?

    Bristol-Myers Squibb was last trading at $63.15 per share. This represents the most recent stock quote for Bristol-Myers Squibb. Yesterday, Bristol-Myers Squibb closed at $61.09 per share.

  • How To Buy Bristol-Myers Squibb Stock Online?

    In order to purchase Bristol-Myers Squibb stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

IBM Stock: Stable Dividend or Stagnant Investment?
IBM Stock: Stable Dividend or Stagnant Investment?

The AI race has heated up significantly but returns on…

Is Trimble Stock a Buy, Sell or Hold?
Is Trimble Stock a Buy, Sell or Hold?

Trimble (NASDAQ:TRMB) is a hardware and software tech company that…

Is DraftKings Stock a Good Bet on the Future of Sports Betting?
Is DraftKings Stock a Good Bet on the Future of Sports Betting?

It seems like right now is a good time to…

Stock Ideas

Buy
62
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Sell
47
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Sell
47
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 38x

Alerts

Buy
86
WLDN alert for Mar 10

Willdan Group [WLDN] is down 3.66% over the past day.

Buy
76
PDEX alert for Mar 10

Pro-Dex [PDEX] is up 10.33% over the past day.

Sell
7
IOT alert for Mar 10

Samsara [IOT] is down 3.68% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock